Characterization of novel CD55 isoforms expression in normal and neoplastic tissues

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• CD55 (decay-accelerating factor, DAF) is overexpressed in cancers like colorectal cancer and is a potential immunotherapy target.
• However, broad CD55 expression in normal tissues limits therapeutic antibody use.
• Two new CD55 splice variants, CD55(int7+), containing intron 7, have been identified.

Purpose of the Study:

• To investigate the expression patterns of CD55(int7+) isoforms in normal and cancerous tissues.
• To compare the expression of CD55(int7+) with the previously identified CD55(wt) variants.
• To evaluate the potential of CD55(int7+) as a more specific target for cancer immunotherapy.

Main Methods:

• Quantitative analysis of CD55 splice variant mRNA levels.
• Immunohistochemical analysis of CD55(int7+) and CD55(wt) protein expression.
• Comparison of isoform expression in normal colon tissue, colorectal tumors, and other pathological conditions.

Main Results:

• CD55(wt) is significantly more abundant (48-fold) than CD55(int7+) in normal tissues.
• Colorectal cancers with high CD55(wt) mRNA levels also show increased CD55(int7+) expression.
• Both isoforms are elevated in colonic pathology, but CD55(int7+) is restricted to epithelial structures in tumors, unlike CD55(wt).

Conclusions:

• CD55(int7+) exhibits significantly lower expression in normal tissues compared to CD55(wt).
• The tumor-specific epithelial expression of CD55(int7+) distinguishes it from CD55(wt).
• CD55(int7+) represents a more targeted and potentially safer therapeutic target for colorectal cancer immunotherapy.